A Phase 1 Trial of MK-1248 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs MK 1248 (Primary) ; Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 20 Apr 2017 Planned End Date changed from 1 Dec 2019 to 23 Mar 2019.
- 20 Apr 2017 Planned primary completion date changed from 1 Nov 2017 to 23 Mar 2019.
- 20 Apr 2017 Status changed from recruiting to active, no longer recruiting.